SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today that its partner, Tripep AB of Sweden, recently demonstrated that Tripep’s proprietary DNA vaccine, ChronVac-C®, administered using Inovio’s MedPulser® DNA Drug Delivery System activated a T-cell response in mice that appears capable of clearing liver cells expressing hepatitis C virus protein in a murine model of hepatitis C.
